1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3 Purity >98.0% (HPLC) Brexpiprazole Intermediate Factory

Short Description:

1-(1-Benzothiophen-4-yl)piperazine Hydrochloride

CAS: 913614-18-3

Purity: >99.0% (HPLC)

Appearance: White to Off-White Powder

Intermediate of Brexpiprazole (CAS: 913611-97-9)

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Brexpiprazole Intermediates
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3
7-(4-Chlorobutoxy)quinolin-2(1H)-one CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3

Chemical Properties:

Chemical Name	1-(1-Benzothiophen-4-yl)piperazine Hydrochloride
Synonyms	Brexpiprazole Intermediate 2; 1-Benzo[b]thien-4-yl-Piperazine Hydrochloride; 1-Benzo[b]thien-4-ylpiperazine Monohydrochloride
CAS Number	913614-18-3
CAT Number	RF-PI1034
Stock Status	In Stock, Production Capacity 100MT/Year
Molecular Formula	C12H15ClN2S
Molecular Weight	254.7789
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Powder
Identification	Retention time of the sample conforms to that of the reference standard
Purity / Analysis Method	>99.0% (HPLC)
Loss on Drying	<0.50%
Water (K.F)	<0.50%
Residue on Ignition	<0.20%
Related Substances	(HPLC)
Any Individual Impurity	<0.50%
Total Impurities	<1.00%
Infrared Spectrum	Conforms to Structure
Proton NMR Spectrum	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Intermediate of Brexpiprazole (CAS: 913611-97-9)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

1-(1-Benzothiophen-4-yl)piperazine Hydrochloride (CAS: 913614-18-3) is an intermediate of Brexpiprazole (CAS: 913611-97-9). Brexpiprazole is a kind of atypical antipsychotic. It is a dopamine D2 receptor partial agonist. As a novel serotonin-dopamine activity modulator, it can be used for the treatment of schizophrenia, and for the adjunctive treatment for depression. It can also provide efficacy and tolerability over established adjunctive treatments formajor depressive disorder(MDD). The drug exhibits a unique pharmacological profile, acting as a partial agonist of serotonin 5-HT1A and dopamine D2 receptors and as a full antagonist of 5-HT2A and noradrenaline α1B/2C receptors, with similar subnanomolar binding affinity. The drug, which was developed by Otsuka and Lundbeck, was approved in 2015 by the FDA for the treatment of schizophrenia and as an adjunctive treatment for depression.